Page last updated: 2024-08-25

rosiglitazone and Bone Loss, Osteoclastic

rosiglitazone has been researched along with Bone Loss, Osteoclastic in 17 studies

Research

Studies (17)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (5.88)	18.2507
2000's	7 (41.18)	29.6817
2010's	9 (52.94)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Balkan, W; Bianco, AC; Cao, Y; Fonseca, TL; Gomes, SA; Gouveia, CH; Hare, JM; Kapiloff, MS; Li, J; Paulino, EC; Rangel, EB; Teixeira, MB	1
Asteian, A; Bruning, JB; Corzo, CA; Czernik, PJ; Griffin, PR; Kamenecka, TM; Lecka-Czernik, B; Marciano, DP; Rosen, CJ; Rotter, ZC; Stechschulte, LA; Tausif, FN; Zheng, J	1
Debiais, F	1
Aftring, RP; Haffner, SM; Herman, WH; Holman, RR; Jones, NP; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Zinman, B	1
Abdullah, SM; Ayers, CR; Fordan, S; Ghayee, HK; Gruntmanis, U; McGuire, DK; See, R	1
Ding, LJ; Ji, H; Ji, JL; Li, YQ; Liu, K; Ma, L; Yu, X	1
Dechow, PC; Evans, RM; Smith, LC; Sonoda, J; Wan, Y; Wang, X; Wei, W; Yang, M	1
Harsløf, T; Langdahl, BL; Møller, L; Pedersen, SB; Ringgaard, S; Stødkilde-Jørgensen, H; Wamberg, L	1
Cho, ES; Kim, MK; Lee, JC; Lee, KS; Park, SM; Son, YO	1
Bookout, AL; Dechow, PC; Ding, X; Dutchak, PA; Gerard, RD; Goetz, R; Kliewer, SA; Mangelsdorf, DJ; Mohammadi, M; Wan, Y; Wang, X; Wei, W	1
Kneissel, M; Seuwen, K; Sottile, V	1
Hogue, WR; Lazarenko, OP; Lecka-Czernik, B; Rzonca, SO; Suva, LJ; Swain, FL	1
Bryant, B; Jain, SK; Yaturu, S	1
Schwartz, AV; Sellmeyer, DE	1
Bianchi, A; Jouzeau, JY; Koufany, M; Moulin, D; Muresan, M; Netter, P; Sebillaud, S; Weryha, G	1
Wahli, W	1
Fujita, T; Fukumoto, S; Miyamoto, M; Okazaki, R; Takeuchi, Y; Tanaka, K; Toriumi, M	1

Trials

3 trial(s) available for rosiglitazone and Bone Loss, Osteoclastic

Article	Year
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:1 Topics: Adult; Aged; Biomarkers; Bone and Bones; Bone Resorption; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Osteogenesis; Rosiglitazone; Thiazolidinediones	2010
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcified tissue international, 2010, Volume: 86, Issue:5 Topics: Biomarkers; Bone Density; Bone Resorption; Collagen Type I; Diabetes Mellitus, Type 2; Double-Blind Method; Ethnicity; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Osteogenesis; Peptide Fragments; Peptides; Postmenopause; PPAR gamma; Procollagen; Reference Values; Rosiglitazone; Texas; Thiazolidinediones	2010
Rosiglitazone decreases bone mass and bone marrow fat. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:5 Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Marrow; Bone Resorption; Collagen Type I; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Lipid Metabolism; Magnetic Resonance Spectroscopy; Middle Aged; Peptides; Postmenopause; PPAR gamma; Rosiglitazone; Thiazolidinediones	2011

Other Studies

14 other study(ies) available for rosiglitazone and Bone Loss, Osteoclastic

Article	Year
S-nitrosoglutathione reductase-dependent PPARγ denitrosylation participates in MSC-derived adipogenesis and osteogenesis. The Journal of clinical investigation, 2015, Volume: 125, Issue:4 Topics: Adipocytes; Adipogenesis; Adiponectin; Alcohol Dehydrogenase; Amino Acid Sequence; Animals; Bone Remodeling; Bone Resorption; Cell Lineage; Fatty Acid-Binding Proteins; Feedback, Physiological; Gene Expression Regulation, Developmental; Glutathione Reductase; HEK293 Cells; Humans; Male; Mesenchymal Stem Cells; Mice; Models, Molecular; Molecular Sequence Data; Nitrosation; Osteoblasts; Osteoclasts; Osteogenesis; Phenotype; PPAR gamma; Protein Conformation; Protein Processing, Post-Translational; Recombinant Fusion Proteins; Rosiglitazone; Thiazolidinediones; Transcription, Genetic	2015
PPARG Post-translational Modifications Regulate Bone Formation and Bone Resorption. EBioMedicine, 2016, Volume: 10 Topics: Adipocytes; Animals; Bone and Bones; Bone Resorption; Cell Line; Energy Metabolism; Male; Mice; Models, Animal; Mutation; Osteoblasts; Osteoclasts; Osteocytes; Osteogenesis; PPAR alpha; PPAR gamma; Protein Processing, Post-Translational; Rosiglitazone; Thiazolidinediones; X-Ray Microtomography	2016
Thiazolidinediones: antidiabetic agents with effects on bone. Joint bone spine, 2009, Volume: 76, Issue:3 Topics: Aged; Animals; Bone and Bones; Bone Density; Bone Resorption; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Humans; Hypoglycemic Agents; Male; Mice; Osteoporosis; Pioglitazone; Randomized Controlled Trials as Topic; Rats; Rosiglitazone; Thiazolidinediones	2009
Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats. Bone, 2010, Volume: 47, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biomarkers; Biomechanical Phenomena; Blood Pressure; Body Weight; Bone Density; Bone Remodeling; Bone Resorption; Female; Heart Rate; Lumbar Vertebrae; Ovariectomy; Rats; Rats, Inbred SHR; Rosiglitazone; Systole; Telmisartan; Thiazolidinediones; Tibia; Time Factors; X-Ray Microtomography	2010
PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell metabolism, 2010, Jun-09, Volume: 11, Issue:6 Topics: Animals; beta Catenin; Bone Resorption; Cell Differentiation; Cell Line; ERRalpha Estrogen-Related Receptor; Humans; Hypoglycemic Agents; Male; Mice; Mice, Knockout; Osteoclasts; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR gamma; Proto-Oncogene Proteins c-jun; Rats; Receptors, Estrogen; Rosiglitazone; Thiazolidinediones; Trans-Activators; Transcription Factors	2010
The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption. Molecules and cells, 2012, Volume: 33, Issue:2 Topics: Adipogenesis; Animals; Bone Marrow Cells; Bone Resorption; Collagen Type I; Mice; NF-kappa B; Osteoblasts; Osteocalcin; Osteoclasts; Osteogenesis; PPAR gamma; RANK Ligand; Rosiglitazone; Thiazolidinediones; Transcriptional Activation	2012
Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proceedings of the National Academy of Sciences of the United States of America, 2012, Feb-21, Volume: 109, Issue:8 Topics: Adipogenesis; Animals; Bone and Bones; Bone Marrow; Bone Resorption; Drug Resistance; Fibroblast Growth Factors; Humans; Mice; Mice, Knockout; Organ Size; Osteoblasts; Osteogenesis; Osteoprotegerin; PPAR gamma; RANK Ligand; Rosiglitazone; Thiazolidinediones	2012
Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcified tissue international, 2004, Volume: 75, Issue:4 Topics: Absorptiometry, Photon; Adipocytes; Animals; Body Weight; Bone Density; Bone Marrow; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Female; Hypoglycemic Agents; Osteoblasts; Ovariectomy; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Tibia; Triglycerides	2004
Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology, 2007, Volume: 148, Issue:6 Topics: Aging; Animals; Bone and Bones; Bone Density; Bone Resorption; Cell Differentiation; Compressive Strength; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Osteoblasts; Osteoclasts; Osteogenesis; Osteoporosis; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed	2007
Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes care, 2007, Volume: 30, Issue:6 Topics: Bone Density; Bone Resorption; Diabetes Mellitus, Type 2; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance? Diabetes care, 2007, Volume: 30, Issue:6 Topics: Bone Density; Bone Resorption; Diabetes Mellitus, Type 2; Fractures, Bone; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis. Arthritis research & therapy, 2008, Volume: 10, Issue:1 Topics: Adiponectin; Adipose Tissue; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Cartilage, Articular; Cytokines; Dose-Response Relationship, Drug; Fever; Fibroblast Growth Factor 2; Hindlimb; Hypoglycemic Agents; Incidence; Male; Pioglitazone; PPAR gamma; Rats; Rats, Inbred Lew; RNA, Messenger; Rosiglitazone; Synovial Membrane; Synovitis; Thiazolidinediones; Weight Gain	2008
PPAR gamma: ally and foe in bone metabolism. Cell metabolism, 2008, Volume: 7, Issue:3 Topics: Animals; Bone Remodeling; Bone Resorption; Cell Differentiation; Cell Lineage; Hematopoietic Stem Cells; Humans; Mice; Mice, Knockout; NF-kappa B; Osteoblasts; Osteoclasts; Osteopetrosis; PPAR gamma; Proto-Oncogene Proteins c-fos; Rosiglitazone; Signal Transduction; Thiazolidinediones	2008
Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology, 1999, Volume: 140, Issue:11 Topics: Acid Phosphatase; Adipocytes; Animals; Bone Marrow Cells; Bone Resorption; Calcitriol; Cell Differentiation; Cells, Cultured; Chromans; Hypoglycemic Agents; Interleukin-11; Isoenzymes; Mice; Mice, Inbred ICR; Osteoclasts; Parathyroid Hormone; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Tartrate-Resistant Acid Phosphatase; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	1999